COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00616499
Recruitment Status : Unknown
Verified September 2008 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
First Posted : February 15, 2008
Last Update Posted : February 9, 2009
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving Gefitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with stage IIIA non-small cell lung cancer.

Condition or disease Intervention/treatment Phase
Lung Cancer Drug: gefitinib Procedure: neoadjuvant therapy Procedure: therapeutic conventional surgery Phase 2

Detailed Description:



  • To assess the response rate to gefitinib treatment as preoperative induction therapy in patients with biopsy-proven stage IIIA (pN2) non-squamous non-small cell lung cancer accompanied by epidermal growth factor receptor (EGFR) mutations.


  • To determine the complete resection rate in patients treated with this drug.
  • To determine the overall survival rate in patients treated with this drug.
  • To determine the disease-free survival rate in patients treated with this drug.
  • To determine the pathologic complete response rate in patients treated with this drug.
  • To determine the toxicity of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral gefitinib once a day on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients with resectable disease may undergo surgery. Patients with unresectable disease may undergo surgery, chemotherapy, and/or radiotherapy.

After completion of study therapy, patients are followed for 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Neoadjuvant Gefitinib Therapy Based on Mutation Study in Biopsy- Proven Stage IIIA N2 Non-Squamous Non-Small Cell Lung Cancer
Study Start Date : November 2006
Estimated Primary Completion Date : November 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Gefitinib

Primary Outcome Measures :
  1. Response rate

Secondary Outcome Measures :
  1. Complete resection rate
  2. Overall survival rate
  3. Median disease-free survival
  4. Complete pathological response rate
  5. Toxicity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Biopsy-proven stage IIIA nonsquamous non-small cell lung cancer

    • pN2 disease proven by mediastinoscopy
  • Meets any of the following criteria:

    • Never smoked
    • EGFR mutations (in exon 18, 19, or 21)*
    • FISH positive for EGFR* NOTE: *Irrespective of smoking history
  • Presence of at least 1 unidimensionally measurable lesion on thoracic CT scan, according to RECIST
  • Feasible to undergo pneumonectomy or lobectomy


Inclusion criteria:

  • ECOG performance status 0-1
  • FEV_1 ≥ 2.0 L in preoperative pulmonary function test
  • Hemoglobin ≥ 9.0 g/dL
  • WBC 4,000-12,000/μL
  • ANC ≥ 1,500/μL
  • Platelet count ≥ 100,000/mm³
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 3.0 times ULN
  • AST and ALT ≤ 3.0 times ULN
  • Creatinine ≤ 1.5 times ULN
  • Negative pregnancy test

Exclusion criteria:

  • Severe complications or infections
  • Pregnant or breast-feeding women
  • Clinically significant heart disease
  • Uncontrolled hepatitis, chronic liver disease, or diabetes mellitus
  • Another active cancer except properly treated carcinoma in situ of the cervix or basal/squamous cell skin carcinoma


  • No prior radiotherapy, chemotherapy, hormone therapy, or target therapy
  • No other concurrent systemic anticancer therapies, including experimental drugs, chemotherapy, immunotherapy, or radiotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00616499

Layout table for location information
Korea, Republic of
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 110-744
Contact: Contact Person    82-2-2072-1742      
Yonsei Cancer Center at Yonsei University Medical Center Recruiting
Seoul, Korea, Republic of, 120-752
Contact: Joo-Hang Kim, MD    82-2-2228-8131   
Samsung Medical Center Recruiting
Seoul, Korea, Republic of, 135-710
Contact: Contact Person    82-2-3410-1247      
Asan Medical Center - University of Ulsan College of Medicine Recruiting
Seoul, Korea, Republic of, 138-736
Contact: Contact Person    82-2-3010-7282      
Sponsors and Collaborators
Yonsei University
Layout table for investigator information
Study Chair: Joo-Hang Kim, MD Yonsei University

Layout table for additonal information Identifier: NCT00616499    
Other Study ID Numbers: CDR0000582623
First Posted: February 15, 2008    Key Record Dates
Last Update Posted: February 9, 2009
Last Verified: September 2008
Keywords provided by National Cancer Institute (NCI):
stage IIIA non-small cell lung cancer
adenocarcinoma of the lung
bronchoalveolar cell lung cancer
large cell lung cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action